Bevacizumab-induced cardiovascular events: a consequence of cholesterol emboli syndrome?

J Natl Cancer Inst. 2007 Jan 3;99(1):85-6. doi: 10.1093/jnci/djk011.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adult
  • Aged
  • Angiogenesis Inhibitors / administration & dosage
  • Angiogenesis Inhibitors / adverse effects*
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Atherosclerosis / complications
  • Bevacizumab
  • Embolism, Cholesterol / chemically induced
  • Embolism, Cholesterol / etiology*
  • Eosinophilia / complications*
  • Female
  • Humans
  • Hypertension / chemically induced*
  • Hypertension / complications
  • Male
  • Middle Aged
  • Neoplasms / drug therapy
  • Prospective Studies
  • Syndrome
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors*

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Vascular Endothelial Growth Factor A
  • Bevacizumab